12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Company News  |  Deals

Bind Therapeutics, AstraZeneca deal

Bind and AstraZeneca partnered to develop and commercialize an Accurin based on an undisclosed kinase inhibitor in the pharma's pipeline for undisclosed cancer indications. Bind used its Medicinal Nanoengineering technology to develop the Accurin, which is a selective and programmable nanoparticle-encapsulated therapeutic designed to accumulate at the site of...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >